CLPTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
ClearPoint Neuro, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$9.17+0.10 (+1.10%)
Close on Oct 19, 2026
- Market cap
- $276.63M
- P/E (TTM)
- –
- Dividend yield
- –
ClearPoint Neuro, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $7.38M | $8.80M | $7.21M | $5.36M | $6.00M | $5.29M | $4.57M | $5.47M | $4.94M | $3.64M | $3.23M | $2.41M | 67.8% | +23.0% |
| Neurosurgery navigation and therapy | $5.55M | $5.89M | $4.70M | $3.42M | $3.43M | $3.28M | $2.91M | $2.86M | $2.59M | $1.93M | $2.04M | $1.92M | 51.0% | +61.8% |
| Neurosurgery Navigation and Therapy - Disposable Products | $5.55M | $5.89M | $4.70M | $3.42M | $3.43M | $3.28M | $2.91M | $2.86M | $2.59M | $1.93M | – | $1.87M | 51.0% | +61.8% |
| Biologics and drug delivery | $4.03M | $4.81M | $5.21M | $4.40M | $4.74M | $4.69M | $4.25M | $4.43M | $4.33M | $4.31M | $4.07M | $3.49M | 37.0% | -14.9% |
| Service and other revenue | $3.50M | $3.33M | $3.20M | $3.50M | $3.22M | $3.19M | $3.20M | $2.65M | $2.91M | $4.00M | $3.58M | $3.35M | 32.2% | +8.9% |
| Biologics and Drug Delivery - Services and License Fees | $3.09M | $2.91M | $2.81M | $3.11M | $2.87M | $2.91M | $2.93M | $2.37M | $2.66M | $3.75M | $3.31M | $3.03M | 28.4% | +7.7% |
| Capital equipment and software | $1.30M | $1.43M | $502.00K | $1.04M | $1.04M | $517.00K | $614.00K | $831.00K | $945.00K | $1.41M | $699.00K | $357.00K | 11.9% | +24.2% |
| Biologics and Drug Delivery - Disposable Products | $943.00K | $1.90M | $2.40M | $1.29M | $1.87M | $1.78M | $1.32M | $2.06M | $1.67M | $553.00K | $759.00K | $455.00K | 8.7% | -49.6% |
| Capital Equipment and Software - Systems and Software Products | $881.00K | $1.02M | $115.00K | $647.00K | $694.00K | $234.00K | $341.00K | $552.00K | $687.00K | $1.16M | $428.00K | $81.00K | 8.1% | +26.9% |
| Capital Equipment and Software - Services | $416.00K | $413.00K | $387.00K | $390.00K | $350.00K | $283.00K | $273.00K | $279.00K | $258.00K | $250.00K | $271.00K | $276.00K | 3.8% | +18.9% |
| Capital Equipment and Software-Related Service | $400.00K | $700.00K | – | – | $200.00K | $800.00K | – | – | – | – | – | – | 3.7% | +100.0% |
| Capital Equipment Related Service Revenue | – | – | – | $200.00K | $200.00K | $800.00K | $100.00K | $200.00K | $500.00K | $1.50M | $100.00K | $200.00K | – | – |
| Functional neurosurgery navigation and therapy | – | – | – | – | – | – | – | – | – | $1.93M | $2.04M | $1.92M | – | – |
| Functional Neurosurgery Navigation and Therapy - Services | – | – | – | – | – | – | – | – | – | $0 | $1.00K | $44.00K | – | – |
| Functional Neurosurgery Navigation and Therapy - Disposable Products | – | – | – | – | – | – | – | – | – | $1.93M | $2.04M | $1.87M | – | – |
| Neurosurgery Navigation and Therapy - Services | – | – | – | – | – | $0 | – | $0 | $0 | $0 | – | $44.00K | – | – |
By region
From the segment and revenue-disaggregation notes of ClearPoint Neuro's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.